Approaches to the therapy of heart failure with reduced ejection fraction. Resolution of an online meeting of the Volga Federal District experts-Reference-Cited by-同舟云学术

Approaches to the therapy of heart failure with reduced ejection fraction. Resolution of an online meeting of the Volga Federal District experts

Published:2021-12-11 Issue:4S Volume:26 Page:4791
ISSN:2618-7620
Container-title:Russian Journal of Cardiology
language:
Short-container-title:Russ J Cardiol

Author:

Galyavich A. S.^ORCID,Fomin I. V.^ORCID,Gaisin I. R.^ORCID,Valeeva F. V.^ORCID,Vinogradova N. G.^ORCID,Salasyuk A. S.^ORCID,Tarlovskaya E. I.^ORCID,Khasanov N. R.^ORCID,Shutov A. M.^ORCID,Volodina E. N.^ORCID,Grekhova L. V.,Guseva P. S.,Duplyakov D. V.^ORCID,Zanozina O. V.^ORCID,Zolotova Yu. V.,Kanysheva S. V.,Kim Z. F.^ORCID,Kononov S. K.,Kuzmin V. P.,Markiyanova S. S.,Menzorov M. V.^ORCID,Pomosov S. A.,Rebrov A. P.^ORCID,Tolstov S. N.^ORCID

Abstract

At an online meeting of experts held on May 14, 2021 additional research results on a sodium-glucose co-transporter-2 (SGLT2) inhibitor empagliflozin in patients with heart failure with reduced ejection fraction were considered. According to the data from the EMPEROR-Reduced international study, cardiovascular and renal effects of empagliflozin therapy in patients with and without type 2 diabetes (T2D) were analyzed. A number of proposals and recommendations was accepted regarding the further study of cardiovascular and renal effects of empagliflozin and its use in clinical practice in patients with heart failure, regardless of the T2D presence.

Publisher

Silicea - Poligraf, LLC

Subject

Cardiology and Cardiovascular Medicine

Reference24 articles.

1. Villevalde SV, Galyavich AS, Vinogradova NG, et al. Resolution of an online meeting of the Volga Federal District experts on the EMPEROR-Reduced trial “A new era in the treatment of patients with HF. From EMPA-REG OUTCOME to EMPEROR-Reduced trial”. Russ J Cardiol. 2021;26(2S):4562. (In Russ.) doi:10.15829/1560-4071-2021-4562.

2. Polyakov DS, Fomin IV, Belenkov YuN, et al. Chronic heart failure in the Russian Federation: what has changed over 20 years of follow-up? Results of the EPOCH-CHF study. Kardiologiia. 2021;61(4):4-14. (In Russ.) doi:10.18087/cardio.2021.4.n1628.

3. Fomin IV. Chronic heart failure in Russian Federation: what do we know and what to do. Russ J Cardiol. 2016;(8):7-13. (In Russ.) doi:10.15829/1560-4071-2016-8-7-13.

4. Packer M, Anker SD, Butler J, et al., EMPEROR-Reduced trial investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413-24. doi:10.1056/NEJMoa2022190.

5. Russian Society of Cardiology (RSC). 2020 Clinical practice guidelines for Chronic heart failure. Russ J Cardiol. 2020;25(11):4083. (In Russ.) doi:10.15829/1560-4071-2020-4083.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rational drug therapy of chronic heart failure: the role of mineralocorticoid receptor antagonists: review;Consilium Medicum;2022-01-15